Notice: This company has been marked as potentially delisted and may not be actively trading. Talaris Therapeutics (TALS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendInsider TradesTrends TALS vs. DNLI, TWST, SWTX, KYMR, VCEL, BEAM, IOVA, RXRX, IBRX, and APGEShould you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include Denali Therapeutics (DNLI), Twist Bioscience (TWST), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Vericel (VCEL), Beam Therapeutics (BEAM), Iovance Biotherapeutics (IOVA), Recursion Pharmaceuticals (RXRX), ImmunityBio (IBRX), and Apogee Therapeutics (APGE). These companies are all part of the "biological products, except diagnostic" industry. Talaris Therapeutics vs. Denali Therapeutics Twist Bioscience SpringWorks Therapeutics Kymera Therapeutics Vericel Beam Therapeutics Iovance Biotherapeutics Recursion Pharmaceuticals ImmunityBio Apogee Therapeutics Denali Therapeutics (NASDAQ:DNLI) and Talaris Therapeutics (NASDAQ:TALS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Do insiders & institutionals believe in DNLI or TALS? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 67.6% of Talaris Therapeutics shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by insiders. Comparatively, 16.5% of Talaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, DNLI or TALS? Denali Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Talaris Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Is DNLI or TALS more profitable? Denali Therapeutics' return on equity of -32.94% beat Talaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -32.94% -30.04% Talaris Therapeutics N/A -39.93%-37.37% Which has preferable earnings & valuation, DNLI or TALS? Talaris Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Talaris Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M9.34-$145.22M-$2.76-7.77Talaris TherapeuticsN/AN/A-$73.89M-$1.79-11.54 Do analysts prefer DNLI or TALS? Denali Therapeutics presently has a consensus target price of $40.40, indicating a potential upside of 88.34%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Denali Therapeutics is more favorable than Talaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82Talaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor DNLI or TALS? Denali Therapeutics received 438 more outperform votes than Talaris Therapeutics when rated by MarketBeat users. Likewise, 67.82% of users gave Denali Therapeutics an outperform vote while only 48.15% of users gave Talaris Therapeutics an outperform vote. CompanyUnderperformOutperformDenali TherapeuticsOutperform Votes45167.82% Underperform Votes21432.18% Talaris TherapeuticsOutperform Votes1348.15% Underperform Votes1451.85% Does the media favor DNLI or TALS? In the previous week, Denali Therapeutics had 11 more articles in the media than Talaris Therapeutics. MarketBeat recorded 11 mentions for Denali Therapeutics and 0 mentions for Talaris Therapeutics. Denali Therapeutics' average media sentiment score of 1.03 beat Talaris Therapeutics' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Denali Therapeutics Positive Talaris Therapeutics Neutral SummaryDenali Therapeutics beats Talaris Therapeutics on 12 of the 16 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. Get Talaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TALS vs. The Competition Export to ExcelMetricTalaris TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$883.08M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-11.5446.7390.0517.18Price / SalesN/A415.011,116.25117.05Price / CashN/A182.1043.1037.85Price / Book4.773.894.784.78Net Income-$73.89M-$42.21M$120.31M$225.60M Talaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TALSTalaris TherapeuticsN/A$20.65+1.5%N/A+8.7%$883.08MN/A-11.5484High Trading VolumeDNLIDenali Therapeutics4.4317 of 5 stars$23.29+1.4%$40.40+73.5%-0.5%$3.35B$330.53M-8.49364Positive NewsTWSTTwist Bioscience2.5467 of 5 stars$48.43+2.0%$51.90+7.2%+32.5%$2.87B$312.97M-13.45990SWTXSpringWorks Therapeutics1.984 of 5 stars$38.01-0.8%$69.50+82.8%+6.6%$2.83B$5.45M-9.87305High Trading VolumeKYMRKymera Therapeutics2.2631 of 5 stars$43.06+2.2%$53.88+25.1%+60.7%$2.79B$87.56M-18.00170Positive NewsVCELVericel1.2886 of 5 stars$56.46-1.8%$59.71+5.8%+59.2%$2.79B$226.84M957.83300Analyst ForecastBEAMBeam Therapeutics3.4396 of 5 stars$28.93+3.6%$47.67+64.8%+3.3%$2.40B$349.64M-16.34461Positive NewsIOVAIovance Biotherapeutics4.0375 of 5 stars$7.84+0.1%$22.33+184.9%-6.5%$2.39B$90.86M-5.28500RXRXRecursion Pharmaceuticals2.4307 of 5 stars$7.44+7.1%$9.25+24.3%-38.7%$2.13B$44.58M-4.85400News CoverageHigh Trading VolumeIBRXImmunityBio2.1671 of 5 stars$3.06+6.6%$17.38+467.8%-35.8%$2.13B$7.33M-3.36590Analyst ForecastHigh Trading VolumeAPGEApogee Therapeutics2.6239 of 5 stars$47.21+6.1%$83.88+77.7%+86.7%$2.13BN/A-18.3991Positive News Related Companies and Tools Related Companies Denali Therapeutics Alternatives Twist Bioscience Alternatives SpringWorks Therapeutics Alternatives Kymera Therapeutics Alternatives Vericel Alternatives Beam Therapeutics Alternatives Iovance Biotherapeutics Alternatives Recursion Pharmaceuticals Alternatives ImmunityBio Alternatives Apogee Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TALS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TALS Stock Alerts